Study of Imaging and Molecular Biomarkers in Uncomplicated Rhegmatogenous Retinal Detachment (NCT07386678) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Study of Imaging and Molecular Biomarkers in Uncomplicated Rhegmatogenous Retinal Detachment
United Kingdom50 participantsStarted 2026-04-27
Plain-language summary
Disease or general study area: Uncomplicated rhegmatogenous retinal detachment (RRD) and risk of proliferative vittroretinopathy (PVR)
Purpose and nature of the study:
1. Characterise the cytokine profile of vitreous fluid in uncomplicated RRD.
2. Develop a risk model to predict development of PVR after retinal detachment surgery using imaging and molecular biomarkers.
3. To develop deep learning/artificial intelligence (AI) models for PVR detection in retinal detachment.
Inclusion criteria:
50 adult ( ≥18 years) patients with uncomplicated rhegmatogenous retinal detachments without PVR.
What participating will involve:
Pre- and post-operative assessments and intervention will follow standard of care for patients with rhegmatogenous retinal detachments.
Additional intervention will include non-invasive imaging of anterior chamber flare, vitreous, wide-field retina, macula optical coherence tomography (OCT) and macula OCT-angiography (OCT-A) as well as, seeking participant's consent on collecting their vitreous fluid at time of their surgery for cytokine analysis.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults ≥18 years
* Uncomplicated primary rhegmatogenous retinal detachment
* PVD present
* No PVR-A/B/C
* Phakic or pseudophakic.
Exclusion Criteria:
* Patients \<18 years
* Patients lacking capacity
* Previous vitrectomy
* Previous cryopexy
* Aphakia
* No fundal view
* Diabetic retinopathy of any severity
* Retinal detachment secondary to infective causes e.g. acute retinal necrosis, toxoplasmosis scars
* Retinal detachment secondary to congenital defects e.g. optic disc pit/coloboma
* Exudative retinal detachment
* Tractional retinal detachment
* Ongoing involvement in another ocular trial.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Characterise the cytokine milieu in an uncomplicated RRD eye.